Type 2 diabetes is a strong risk factor for coronary artery disease (CAD). However, the absence of a clear reduction in CAD by intensive glucose lowering in randomized controlled trials has fuelled uncertainty regarding the causal role of dysglycaemia and CAD.
Introduction
Type 2 diabetes is a strong risk factor for coronary artery disease (CAD). However, the absence of a clear reduction in CAD by intensive glucose lowering in randomized controlled trials has fuelled uncertainty regarding the causal role of dysglycaemia and CAD.
Objective
To assess whether Mendelian randomization supports a causal role of dysglycaemia and diabetes for risk of CAD.
Methods
Effect size estimates of common genetic variants associated with fasting glucose (FG), glycated haemoglobin (HbA 1c ), and diabetes were obtained from the Meta-Analyses of Glucose and Insulin-Related Traits Consortium and Diabetes Genetics Replication and Meta-Analysis consortia. The corresponding effect estimates of these single nucleotide polymorphisms (SNPs) on the risk of CAD were then evaluated in CARDIOGRAMplusC4D.
Results
SNPs associated with HbA 1c and diabetes were associated with an increased risk of CAD. Using information from 59 genetic variants associated with diabetes, the causal effect of diabetes on the risk of CAD was estimated at an odds ratio (OR) of 1.63 (95% Confidence Interval (CI): 1.23-2.07; P ¼ 0.002). On the other hand, nine genetic variants associated with HbA 1c were associated with an OR of 1.53 per 1% HbA 1c increase (95% CI: 1.14-2.05; P ¼ 0.023) in the risk of CAD while this effect was non-significant among 30 genetic variants associated with FG per mmol/L (OR: 1.18, 95% CI: 0.97-1.42; P ¼ 0.102). No significant differences were observed when categorizing genetic loci according to their effect on either b-cell dysfunction or insulin resistance.
Introduction
Large prospective observational studies have reported that type 2 diabetes increases the risk of cardiovascular events by 2-fold following the adjustment for other risk factors. 1 These and other studies have also reported a progressive relationship between various measures of glycaemia, including fasting glucose (FG) and glycated haemoglobin (HbA 1c ), and cardiovascular outcomes, both in people with diabetes and in people without a history of diabetes or cardiovascular events. 1, 2 Conversely, large randomized controlled trials assessing the effect of glucose lowering have also yielded mixed results. 3 -7 For instance, meta-analyses have demonstrated a modest 9% reduction in the composite cardiovascular outcome and a 15% reduction in coronary artery disease (CAD). 8 -10 Moreover, at least one analysis suggests that this effect on CAD is due to the effect of the intervention on HbA 1c .
11
The conflicting reports from epidemiological studies and clinical trials regarding the potential effects of dysglycaemia on cardiovascular outcomes have fuelled uncertainty regarding the etiologic relationship between dysglycaemia and CAD. However, Mendelian randomization analyses may help to clarify the relationship between glucose traits, diabetes, and risk of CAD. This approach uses genetic associations to explore the effects of modifiable exposures on outcomes. It is based on the principle that genetic variants are randomly allocated at birth and this distribution is independent of many factors that may bias observational associations, 12 such as confounding factors and reverse causation. 13 However, this approach does not rule out the possibility that genetic variants associated with dysglycaemia may also be correlated with other CAD risk factors such as dyslipidaemia, blood pressure elevation, or weight gain. 12 This limitation can be circumvented by adopting the method proposed by Do et al. 14 to adjust Mendelian randomization analyses for genetic effects on these other risk factors. This approach allows for the dissection of causal influences for the risk of CAD among sets of correlated glucose traits and CAD risk factors. To explore the relationship between dysglycaemia-related indices (i.e. FG, HbA 1C and diabetes) and the risk of CAD, we identified genetic variants associated with these three indices and then confirmed whether their genetic effect supports a causal association with CAD. We also explored whether genetic variants that modify b-cell function have a different relationship to CAD than variants that modify insulin resistance.
Methods

Data sources
All single nucleotide polymorphism (SNP) associations were taken from public repositories of genome-wide databases, where each of .3 million SNPs are tested for their relationship with a given outcome using data from .80 000 individuals. Effect size estimates for single SNPs associated with glucose traits (FG and HbA 1C ) were obtained from the MetaAnalyses of Glucose and Insulin-Related Traits Consortium (MAGIC) study, a genome-wide association study (GWAS) consisting of .133 010 of European descent without diabetes. 15 -17 Genetic data for the association of diabetes was obtained from the Diabetes Genetics Replication and Meta-Analysis (DIAGRAM) Consortium study, a GWAS of 34 840 cases and 114 981 controls of European descent. 18 Genetic data for the association of the risk of CAD was obtained from the Coronary Artery Disease Genome-wide Replication and Meta-Analysis (CARDIoGRAMplusC4D) Consortium study, a two-stage GWAS of 63 746 cases of CAD and 130 681 controls. 19 When not available in CARDIoGRAMplusC4D, effect estimates were obtained from the CARDIo-GRAM, which is a meta-analysis of 22 GWAS studies of 22 233 cases and 64 762 controls. 20 Coronary artery disease outcomes were defined as one of the following: myocardial infarction (MI), .50% stenosis in at least one coronary vessel at angiography, history of percutaneous transluminal coronary angioplasty or coronary artery bypass graft surgery, angina or death due to CAD. 19 Genetic data on the association of low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol (TC), and triglycerides (TG) were obtained from the Global Lipids Genetics Consortium study, a GWAS of 188 577 individuals from 60 studies. 21 Genetic data for the association of body mass index (BMI) was obtained from the Genetic Investigation of Anthropometric Traits (GIANT) GWAS in .133 154 European individuals. 22 Further details of each consortium are included in the Supplementary material online, Methods.
SNP selection
SNPs were selected if they were associated with at least one of the two glucose traits (FG and HbA 1C ) or diabetes at genome-wide-level significance of P , 5 × 10
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. For duplicate SNPs and SNPs associated with glucose trait or diabetes that were ,500 kb apart, we obtained the linkage disequilibrium estimates using data from the 1000 Genomes Pilot 1 23 and then assigned a lead SNP based on the strength of association with either glucose traits or diabetes (Supplementary material online, Figure S1 ).
Statistical analysis
We first tested FG, HbA 1c , and diabetes separately for the risk of CAD. This was done by using the effect estimates of SNPs associated with FG, HbA 1c , or diabetes with their corresponding genetic effect estimates on CAD using data from the MAGIC, DIAGRAM, and CARDIOGRAMplusC4D consortia, respectively. Figure 1 represents the schematic representation of the Mendelian Randomization design. Linear regressions (without intercept) were performed using the effect estimates of SNPs on FG, HbA 1C , and diabetes as the independent variables and the genetic effect sizes on CAD as the dependent variable. Since SNPs associated with dysglycaemia may not only be directly associated with the risk of CAD but also with other CAD risk factors, we adjusted the causal effect of dysglycaemia on the risk of CAD for other CAD risk factors. This was done by developing multivariate models adjusting the effect of each SNP on CAD for its genetic effect on LDL, HDL, TC, TG, and BMI. Throughout the manuscript, the effect of the SNPs associated with diabetes on the risk of CAD was expressed as the relative risk of CAD among diabetic individuals when compared with individuals without diabetes. Here, literature estimates of the prevalence of diabetes and the prevalence of CAD in non-diabetic individuals were obtained, 1,2,24 and these estimates were applied to derive the relative risk of CAD associated with diabetes (further details in Supplementary material online, Methods). Estimates of FG available in units of mg/dL were converted to mmol/L using a multiplication factor of 0.055. Genetic effects of fasting glucose and HbA 1c on risk of CAD were expressed per 1 mmol/L and 1% genetic increase in fasting glucose and HbA 1c , respectively. Next, the causal effects of glucose traits and diabetes on the risk of CAD derived from Mendelian randomization were compared with estimates obtained from observational studies to determine if there was a similar magnitude of effect. We compared the magnitude of the genetic effect for the risk of CAD to the effect obtained from observational studies using a z-test based on the Altman and Bland method. 25 We also derived power estimates of the causal effect of SNPs associated with glucose traits and diabetes on the risk of CAD using simulations. To do so, we first calculated the predicted effect of each SNP on CAD by matching their effect on glycaemia or diabetes with expected effect on CAD based on estimates from observational studies. We then performed 10 000 random simulations, regressing the predicted effect of each SNP on CAD on their known effect on glucose traits and diabetes. Finally, loci were categorized according to their effect on 'b-cell dysfunction' or 'insulin resistance' to determine if association with CAD could be ascribed to either hypo-or hyperinsulinaemia, respectively. Only SNPs with an unequivocal effect on 'b-cell dysfunction' or 'insulin resistance' based on literature reviews were included in this analysis, with all SNPs of unknown function or with conflicting reports excluded. All statistical analyses were performed using R.
Results
Association of glucose levels and diabetes with risk of coronary artery disease
Thirty SNPs were associated with FG, 15 nine associated with HbA 1C , 17 and 59 associated with diabetes. 18 Further details on the risk alleles and minor allele frequencies for the trait-specific SNPs are presented in Supplementary material online, Table S1 . To investigate the consistency and directional effect of SNPs association with glucose traits and CAD, we plotted the effect of SNPs on FG, HbA 1c , and diabetes with their corresponding effect on risk of CAD ( Figure 2) . Next, to explore whether SNPs associated with glucose traits and diabetes predict the risk of CAD, we performed linear regression analyses for each trait using the respective effect sizes of SNPs on FG, HbA 1c , and diabetes as the independent variables with the corresponding effects sizes for CAD as the dependent variables ( Figure 3 We sought to determine whether the causal effects of glycaemia and diabetes on the risk of CAD estimated using Mendelian randomization were consistent with the aforementioned estimates obtained from the ERFC (Figure 4) . We observed that the causal effects of diabetes on the risk of CAD derived from our Mendelian randomization was similar to that of the risk estimates obtained from the ERFC (P for difference ¼ 0.161). There were also no statistical differences for glucose traits SNPs and the corresponding literature estimates (P for difference .0.05 for all). Using reported risk estimates from observational studies, we estimated power to detect a genetic association between CAD and diabetes at 100%, 72.2% for HbA 1C , and 5.6% for FG.
Effect of gene function on coronary artery disease risk estimates
We also explored whether the causal association of diabetes with CAD differed between sets of genes known to influence either 
Discussion
Using genetic information from 59 SNPs with known association with diabetes, our Mendelian randomization analysis supports a causal role of diabetes for CAD. We demonstrated that SNPs associated with HbA 1C and diabetes were associated with an increased risk of CAD, which is consistent with findings from large observational studies. 1,2 Furthermore, consistent results were obtained when restricting the analysis to genes affecting either b-cell dysfunction or insulin resistance, suggesting that the therapeutic interventions that act through these different pathways have the potential to reduce CAD irrespective of their mechanism of action. Although our estimates of the effect of diabetes on CAD appeared to be more modest in comparison with observational studies 1,2 this may be explained by residual confounding or bias among these studies. SNPs associated with HbA 1C were also associated with an increased risk of CAD but the effect was attenuated after adjustment for other CAD risk factors. SNPs associated with FG were not associated with the risk of CAD but we had limited power to detect an effect for FG (5.6%). These analyses have several strengths. First, the random allocation of genetic variants acts to reduce the potential effects of confounding and reverse-causation observed in epidemiological studies. Furthermore, unlike other Mendelian randomization analyses that have assessed the effect of glucose traits on the risk of CVD outcomes, 26 we were able to control for genetic effects on other CAD risk factors such as blood lipids, blood pressure, and obesity. We also had very robust estimates from the CARDIOGRAMplusC4D, DIAGRAM, GIANT, GLGC, and MAGIC consortia which collectively included a total of 681 875 individuals. The differences we observed between carriers and non-carriers of genetic variants represent lifelong effects on HbA 1C and diabetes. Indeed, in the UKPDS trial, the authors reported a non-significant reduction in the risk of MI among patients randomized to intensive or conventional glucoselowering strategies. 27 In addition, after 8.5 years of post-trial observations, those originally randomized to the active arm experienced a 15% reduction in MI (P ¼ 0.01) and 13% reduction in all-cause mortality (P ¼ 0.007). 28 Similar trends were also observed in the DCCT/ EDIC trial. 29 Thus, the genetic properties of our analysis provide further support that long-term treatment with glucose-lowering agents may be beneficial. Also, loci involved in b-cell dysfunction and insulin resistance were both associated with CAD. While the causal effect of diabetes on CAD using all SNPs was nominally lower than in each individual subgroup, these differences may be due to fewer SNPs in each subgroup with wider confidence intervals and the exclusion of SNPs with unknown function. Taken together, these results suggest that long-term treatment with glucose-lowering agents, regardless of the mechanism of action, may be required before the effects of glycaemic intervention on CVD events may be observed.
There are several limitations in our study. First, the definition of diabetes used in the DIAGRAM consortium was specific to each cohort, which might introduce heterogeneity into results. Second, estimates obtained from the DIAGRAM and CARDIOGRAMplusC4D consortia consist of both incident and prevalent cases from prospective and case -control studies. Third, owing to a lack of genetic data, we were only able to explore the genetic effect of glucose traits and diabetes in predominantly European populations and we were also unable to account for other confounders that might influence the effect of SNPs associated with glycaemia traits and diabetes on the risk of CAD, such as smoking and waist-to-hip ratio. Fourth, due to the lack of statistical power, we were limited in our ability to evaluate associations with FG. Fifth, we were unable to assess whether there was a non-linear trend for glycaemia traits and the risk of CAD using Mendelian randomization since we did not have individual level data. 30 Finally, we were not able to assess the mechanism of action for all SNPs included in this analysis owing to a lack of functional data in the literature. In summary, our genetic analysis provides further insight into the causal role of glucose levels, diabetes, and the risk of CAD. Our results support that diabetes has an independent and causal effect on the risk of major cardiovascular events. Thus improved glycaemic control among diabetic patients and prevention of diabetes may reduce the risk of CAD outcomes. Our results emphasize the need to further explore the benefits of long-term glucose lowering on CAD.
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Supplementary material is available at European Heart Journal online.
